Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series.

Berkovich R, Calkwood J, Crayton H, Erwin A, Faissner S, Gold R, Katz J, Leekoff M

DOI: 10.3389/fimmu.2025.1609054
Published: 2025
Container: Frontiers in immunology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2025.1609054,
  title = {Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series.},
  author = {Berkovich R and Calkwood J and Crayton H and Erwin A and Faissner S and Gold R and Katz J and Leekoff M},
  year = {2025},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2025.1609054},
  url = {https://doi.org/10.3389/fimmu.2025.1609054}
}

RIS

TY  - JOUR
TI  - Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series.
AU  - Berkovich R
AU  - Calkwood J
AU  - Crayton H
AU  - Erwin A
AU  - Faissner S
AU  - Gold R
AU  - Katz J
AU  - Leekoff M
PY  - 2025
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2025.1609054
UR  - https://doi.org/10.3389/fimmu.2025.1609054
ER  -

APA

R, B., J, C., H, C., A, E., S, F., R, G., J, K., & M, L. (2025). Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2025.1609054

Source records

pubmed · retrieved 2026-09-27T00:19:05.416Z